Analysts at Leerink Partnrs raised their FY2026 EPS estimates for shares of Travere Therapeutics in a research note issued to investors on Tuesday, February 11th. Leerink Partnrs analyst J. Schwartz ...
Research analysts at Leerink Partnrs upped their Q3 2025 EPS estimates for shares of Waters in a note issued to investors on ...
Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class ...
Last year, Bristol Myers Squibb devoted half a page of its annual report to its diversity, equity and inclusion efforts, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback